Sheng-Nan Lu Selected Research

entecavir

1/2022	Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients.
1/2022	Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse.
1/2022	Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
1/2021	The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
1/2021	Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.
12/2020	Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
12/2020	Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
11/2020	Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
7/2020	Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.
5/2020	On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sheng-Nan Lu Research Topics

Disease

88	Hepatocellular Carcinoma (Hepatoma) 10/2022 - 07/2002
74	Fibrosis (Cirrhosis) 10/2022 - 03/2002
64	Infections 10/2022 - 01/2002
60	Chronic Hepatitis B 01/2022 - 01/2002
44	Chronic Hepatitis C 03/2022 - 12/2002
28	Neoplasms (Cancer) 01/2022 - 02/2002
25	Hepatitis B 10/2022 - 01/2002
20	Hepatitis C 10/2021 - 03/2002
17	Liver Cirrhosis (Hepatic Cirrhosis) 04/2021 - 03/2002
15	Liver Diseases (Liver Disease) 10/2022 - 07/2005
12	Hepatitis 01/2015 - 01/2002
9	Liver Neoplasms (Liver Cancer) 01/2021 - 05/2004
7	Viremia 10/2008 - 03/2003
6	Disease Progression 01/2021 - 10/2014
5	Inflammation (Inflammations) 10/2019 - 03/2004
5	Thrombosis (Thrombus) 01/2018 - 01/2009
5	Hemorrhage 07/2017 - 09/2011
5	Persistent Infection 06/2011 - 05/2005
4	Hypertension (High Blood Pressure) 01/2020 - 01/2015
4	Diabetes Mellitus 01/2020 - 05/2011
4	Virus Diseases (Viral Diseases) 01/2019 - 05/2003
4	End Stage Liver Disease 06/2017 - 01/2014
4	Thrombocytopenia (Thrombopenia) 06/2014 - 11/2006
4	Peptic Ulcer (Peptic Ulcers) 01/2014 - 09/2003
3	Neoplasm Metastasis (Metastasis) 12/2021 - 03/2007
3	Varicose Veins (Varicose Vein) 04/2021 - 10/2014
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2020 - 01/2017
3	Ascites 01/2015 - 03/2009
3	Hepatic Encephalopathy 01/2015 - 07/2005
3	Overweight 11/2012 - 11/2008
3	Necrosis 03/2010 - 03/2008
2	Anemia 01/2020 - 11/2006
2	Chronic Renal Insufficiency 01/2020 - 07/2017
2	Body Weight (Weight, Body) 12/2019 - 11/2006
2	Liver Failure 01/2018 - 07/2005
2	Alcoholism (Alcohol Abuse) 04/2015 - 01/2014
2	Fatty Liver 08/2014 - 01/2013
2	Chronic Hepatitis (Chronic Active Hepatitis) 08/2014 - 05/2010

Drug/Important Bio-Agent (IBA)

53	Hepatitis B Surface Antigens (HBsAg)FDA Link 10/2022 - 01/2002
41	Hepatitis B e AntigensIBA 10/2022 - 07/2002
37	Antiviral Agents (Antivirals)IBA 10/2022 - 10/2005
30	entecavir FDA Link 01/2022 - 03/2012
29	InterferonsIBA 12/2020 - 12/2002
29	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 12/2002
26	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 04/2004
25	Alanine Transaminase (SGPT)IBA 02/2022 - 03/2002
19	alpha-Fetoproteins (alpha-Fetoprotein)IBA 10/2022 - 03/2002
17	Tenofovir (Viread)FDA Link 01/2022 - 01/2015
15	RNA (Ribonucleic Acid)IBA 08/2020 - 05/2003
14	Lamivudine (Epivir)FDA Link 12/2017 - 01/2002
11	AlbuminsIBA 04/2022 - 10/2007
11	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2022 - 03/2009
11	AntigensIBA 01/2022 - 11/2008
10	Sorafenib (BAY 43-9006)FDA Link 10/2021 - 06/2013
9	BilirubinIBA 04/2022 - 07/2005
8	Surface Antigens (Surface Antigen)IBA 11/2020 - 07/2012
7	Fetal Proteins (Fetoprotein)IBA 01/2020 - 03/2009
6	Transaminases (Aminotransferases)IBA 04/2021 - 08/2004
5	peginterferon alfa-2a (Pegasys)FDA Link 12/2020 - 02/2009
4	EnzymesIBA 02/2022 - 05/2005
4	Messenger RNA (mRNA)IBA 12/2021 - 05/2004
4	lipoarabinomannan (LAM)IBA 06/2014 - 01/2010
4	adefovirIBA 02/2011 - 07/2005
4	Ethanol (Ethyl Alcohol)IBA 03/2010 - 05/2006
3	VaccinesIBA 10/2022 - 12/2005
3	Blood Glucose (Blood Sugar)IBA 01/2022 - 03/2010
3	SofosbuvirIBA 10/2021 - 01/2020
3	glecaprevir and pibrentasvirIBA 10/2021 - 01/2020
3	Anti-Bacterial Agents (Antibiotics)IBA 05/2021 - 09/2011
3	Hemoglobins (Hemoglobin)IBA 01/2020 - 11/2006
3	Pharmaceutical PreparationsIBA 01/2019 - 05/2011
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2016
3	Aflatoxin B1 (Aflatoxin B)IBA 01/2018 - 04/2015
3	CytokinesIBA 06/2016 - 08/2009
3	Biological ProductsIBA 04/2015 - 01/2006
3	AntibodiesIBA 10/2014 - 07/2002
3	AdiponectinIBA 08/2014 - 08/2009
3	Interferon-alpha (Interferon Alfa)IBA 03/2014 - 03/2003
3	Proteins (Proteins, Gene)FDA Link 01/2013 - 12/2007
2	Cisplatin (Platino)FDA LinkGeneric 06/2022 - 01/2014
2	AcidsIBA 10/2021 - 09/2003
2	velpatasvirIBA 10/2021 - 06/2021
2	lenvatinibIBA 01/2021 - 01/2021
2	dasabuvirIBA 01/2019 - 01/2019
2	ombitasvirIBA 01/2019 - 01/2019
2	paritaprevirIBA 01/2019 - 01/2019
2	Ritonavir (Norvir)FDA Link 01/2019 - 01/2019
2	Telbivudine FDA Link 07/2017 - 03/2012
2	Calcitriol Receptors (Calcitriol Receptor)IBA 04/2016 - 08/2014
2	ORALIT (ORS)IBA 01/2016 - 07/2010
2	ProteomeIBA 07/2015 - 01/2008
2	InterleukinsIBA 05/2015 - 08/2009

Therapy/Procedure

78	Therapeutics 10/2022 - 01/2002
11	Radiofrequency Ablation 06/2022 - 03/2010
7	Aftercare (After-Treatment) 01/2020 - 02/2009
6	Liver Transplantation 01/2020 - 09/2013
6	Drug Therapy (Chemotherapy) 01/2019 - 01/2002
4	Antibiotic Prophylaxis 01/2014 - 09/2011
3	Radiotherapy 06/2022 - 02/2002
3	Retreatment 01/2022 - 01/2019